Organon's Vtama Cream Receives Recommendation from American Academy of Dermatology

Organon's Vtama cream has been recommended by the American Academy of Dermatology for the management of moderate to severe atopic dermatitis in adults. Vtama cream is a steroid-free option for daily disease management with no label warnings or precautions, no contraindications, and no restrictions on duration of use or percentage of body surface area affected.

The American Academy of Dermatology (AAD) has provided a strong evidence-based recommendation for the use of VTAMA cream in adults with moderate to severe atopic dermatitis (AD). This recommendation underscores VTAMA cream's proven efficacy, safety, and tolerability as a steroid-free, topical aryl hydrocarbon receptor agonist [1].

AD impacts approximately 26 million people in the United States, with 16.5 million of these being adults [2]. The AAD's 2025 focused guideline update for managing AD in adults now includes VTAMA cream as an effective, steroid-free option for daily disease management. The cream has no label warnings or precautions, no contraindications, and no restrictions on duration of use or the percentage of body surface area affected [1].

Organon, a global healthcare company with a focus on women's health, announced this strong recommendation from the AAD. The company is proud of the AAD's endorsement based on the findings from the ADORING 1 and ADORING 2 8-week clinical trials for VTAMA cream [1].

In addition to its approval for AD, VTAMA cream was also approved by the FDA in December 2024 for the topical treatment of AD in adults and pediatric patients aged 2 years and older. The cream is indicated for the topical treatment of plaque psoriasis in adults as well [1].

The most common adverse reactions in AD, reported at an incidence of ≥1%, include upper respiratory tract infection, folliculitis, lower respiratory tract infection, headache, asthma, vomiting, ear infection, pain in extremity, and abdominal pain [1].

Organon's VTAMA cream has the potential to redefine the AD treatment landscape, providing lasting relief for millions of adults suffering from this condition [1].

References:
[1] https://www.organon.com/news/organons-vtama-tapinarof-cream-1-granted-strong-recommendation-in-the-american-academy-of-dermatology-updated-2025-guidelines-for-adult-atopic-dermatitis/
[2] https://www.marketscreener.com/quote/stock/ORGANON-CO-122796891/news/Organon-s-VTAMA-Cream-1-Granted-Strong-Recommendation-in-the-American-Academy-of-Dermatology-U-50448055/